Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | KMX | Common Stock | Options Exercise | +2.44K | +18.68% | 15.5K | May 1, 2023 | Direct | F1 | ||
transaction | KMX | Common Stock | Tax liability | -$51.7K | -733 | -4.73% | $70.48 | 14.8K | May 1, 2023 | Direct |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | KMX | Restricted Stock Units | Options Exercise | $0 | -2.69K | -100% | $0.00* | 0 | May 1, 2023 | Common Stock | 2.44K | Direct | F1, F2 | |
transaction | KMX | Stock Options (Right to Buy) | Award | $0 | +37.3K | $0.00 | 37.3K | May 1, 2023 | Common Stock | 37.3K | $70.48 | Direct | F3, F4 |
Id | Content |
---|---|
F1 | Following vesting of the restricted stock units, which are referred to by the Company as market stock units (MSUs), the Reporting Person received 0.91 times the number of MSUs in shares of Company common stock. |
F2 | The restricted stock units vested on May 1, 2023 and were settled in Company common stock. |
F3 | The stock options were granted in tandem with stock appreciation rights (SARS). Accordingly, the exercise of one results in the surrender to the Company of the other. The SARS become exercisable only following a change in control of the Company as set forth in the Company's 2002 Stock Incentive Plan, as amended and restated. Once exercisable, the SARS would entitle the Reporting Person to receive the cash value of the options in lieu of exercising the options. |
F4 | The stock options become exercisable with respect to one-fourth of the underlying shares of Common Stock on each of May 1, 2024, May 1, 2025, May 1, 2026 and May 1, 2027. |